BioSight
Carmiel
About BioSight
BioSight is a biopharmaceutical private company founded in 2000 and re launched in mid 2009, revolutionizing the research and development of innovative cancer targeted pro-drugs. BioSight has developed technology S2DOT TM and a pipeline of targeted pro-drugs, that can target and release chemotherapy drugs inside cancer cells, while significantly minimizing the systemic toxicity associated with conventional chemotherapy treatments.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $59.0M
- Funding stage: M&A
- Last round: Series C (Dec 2020)
- Website: biosight-pharma.com
- Phone: +972.3.6568669
Industries & Categories
Biotechnology, Health Care, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/biosight-169351 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.